HI
CUE icon

Harbour Investments’s Cue Biopharma CUE Stock Holding History

Harbour Investments’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15
Closed -$332 – 3508
2024
Q3 		$332 Hold
15
– – ﹤0.01% 3235
2024
Q2 		$544 Hold
15
– – ﹤0.01% 3077
2024
Q1 		$830 Hold
15
– – ﹤0.01% 2966
2023
Q4 		$1.16K Hold
15
– – ﹤0.01% 2792
2023
Q3 		$1.01K Hold
15
– – ﹤0.01% 2702
2023
Q2 		$1.6K Hold
15
– – ﹤0.01% 2602
2023
Q1 		$1.57K Hold
15
– – ﹤0.01% 2607
2022
Q4 		$1.25K Hold
15
– – ﹤0.01% 2641
2022
Q3 		$1K Hold
15
– – ﹤0.01% 2553
2022
Q2 		$1K Buy
+15
New +$1.75K ﹤0.01% 2553
2021
Q4 		$5K Hold
15
– – ﹤0.01% 2161
2021
Q3 		$6K Hold
15
– – ﹤0.01% 2887
2021
Q2 		$5K Hold
15
– – ﹤0.01% 3034
2021
Q1 		$5K Buy
+15
New +$6.17K ﹤0.01% 2895

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Harbour Investments's CUE Position: Q4 2024 in Review

Harbour Investments sold out of Cue Biopharma (CUE) in Q4 2024, closing a stake of 15 shares — an estimated $332 sold.

Harbour Investments first reported a position in CUE in Q1 2021 and held it in 14 quarters. The position peaked at $6K in Q3 2021. 54 funds tracked by Wall St. Rank hold CUE as of Q4 2024.

  • Harbour Investments reported no remaining Cue Biopharma position as of Q4 2024 after selling out during the quarter.
  • Harbour Investments sold 15 Cue Biopharma shares in Q4 2024, an estimated $332.
  • Harbour Investments first reported a position in Cue Biopharma in Q1 2021 and held it in 14 quarters.
  • Harbour Investments's Cue Biopharma position peaked at $6K in Q3 2021.
  • 54 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2024.

Based on Harbour Investments's 13F filing for Q4 2024, filed 10 Feb 2025.